Abstract
Serotonin and its receptors are widely distributed in the central nervous system (CNS), and changes in serotonergic neurotransmission have been associated with a variety of neurological and psychiatric conditions, including schizophrenia, depression, affective disorders, infantile autism, mental retardation, hyperactivity syndromes, eating disorders, sleep disorders, suicidal behavior, Alzheimer's disease, Duchenne muscular dystrophy, Parkinson's disease, Huntington's chorea, and migraine headaches. This association between serotonin and psychiatric disease has triggered the development of drugs that inhibit serotonin re-uptake and modulate postsynaptic events for treating depression, schizophrenia, eating disorders, and a variety of other conditions.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
